Trinity College Dublin Warns: Alzheimer’s Therapeutic Breakthroughs May Remain Financially Out of Reach

In a groundbreaking study published on May 13, 2026, researchers at Trinity College Dublin reveal a concerning paradox surrounding new Alzheimer’s disease therapies: despite their clinical promise, these revolutionary treatments may remain financially out of reach for patients worldwide. The research, featured in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, offers a sobering analysis of the cost-effectiveness and value-based pricing of two cutting-edge drugs, lecanemab and donanemab, across 174 countries, exposing a global healthcare equity crisis in the making.

For decades, therapeutic options for Alzheimer’s disease have been frustratingly limited to symptomatic relief, unable to alter the relentless progression of this neurodegenerative disorder. The advent of disease-modifying therapies (DMTs) such as lecanemab and donanemab heralds a new chapter, offering the unprecedented possibility of slowing disease progression in its early stages. Yet, accessibility to these treatments hinges critically not on their scientific promise but on the economic realities that different health systems face. This research underscores that a breakthrough in medical science is not synonymous with a breakthrough in patient accessibility.

The investigators employed advanced computational simulation models to emulate lifelong disease trajectories in individuals diagnosed with early-stage Alzheimer’s. This sophisticated modeling framework compared clinical outcomes and costs incurred when patients receive either lecanemab or donanemab alongside standard care, against outcomes from usual care alone. Unlike earlier economic evaluations confined to high-income countries, this expansive study integrates diverse healthcare settings from low- and middle-income nations, offering a comprehensive global perspective.

Their findings are stark: current market prices for lecanemab and donanemab substantially exceed the value-based price thresholds considered cost-effective by health systems in most countries examined. In quantitative terms, lecanemab’s market price overshoots its value-based price by over 180%, while donanemab surpasses it by approximately 130%. This discrepancy signals formidable barriers in the adoption and reimbursement of these therapies, potentially delaying or precluding access for millions of patients worldwide.

This price disparity fuels a pressing global equity dilemma. The economic feasibility of reimbursing these drugs varies dramatically across nations, with the United States representing an outlier capable of sustaining higher pharmaceutical expenditures. Meanwhile, many countries with constrained healthcare budgets—particularly those in lower-income brackets—face an insurmountable challenge in funding these treatments without substantial price concessions. Without adopting differential pricing strategies tailored to local economic contexts, a large swath of the world’s population with Alzheimer’s may remain excluded from cutting-edge care.

Dr. Dominic Trépel, Associate Professor of Health Economics at Trinity College Dublin and principal investigator of the study, emphasized the importance of moving beyond approval towards access. He stressed that while these drugs are scientific milestones, their ability to alter patient trajectories will be fundamentally compromised if healthcare systems cannot afford them. The study endeavors to provide a data-driven foundation for policymakers and pharmaceutical companies to engage in more equitable and sustainable pricing negotiations globally.

The implications of this study extend far beyond mere pricing. By bridging economic evaluation and clinical innovation, it highlights health economics as a critical nexus where biomedical advances encounter practical healthcare decision-making. As health systems grapple with tightening budgets and competing priorities, rigorous cost-effectiveness analyses become indispensable tools to ensure that breakthroughs translate into tangible patient benefits rather than remain theoretical promises.

Moreover, the research underscores the necessity for a dynamic and iterative approach to evaluating Alzheimer’s therapies. This includes augmenting real-world evidence on treatment effectiveness, monitoring adverse events, treatment adherence, and economic impacts over extended time horizons. Such data will refine valuation models and bolster the reliability of recommendations informing reimbursement policies.

Trinity College Dublin’s team plans to expand this framework by collaborating with Atlantic Fellows at the Global Brain Health Institute, enabling regional adaptations based on local epidemiology, healthcare infrastructure, and economic conditions. This participatory approach seeks to empower diverse stakeholders—clinicians, policymakers, patient advocates, and manufacturers—to harmonize clinical potential with financial sustainability.

Significantly, the researchers advocate for transparency and open science by aiming to release their simulation model as an open-source platform. This initiative promises to democratize access to robust economic analysis tools, facilitating broader application in dementia research, as well as informing resource allocation decisions for a spectrum of interventions beyond pharmacotherapy.

For people living with early Alzheimer’s and their families, these findings spotlight a bittersweet reality: the dawn of transformative treatment options may not translate into immediate relief due to financial barriers embedded within global healthcare systems. Clinicians face the dilemma of navigating treatment recommendations amid uneven coverage landscapes, while payers and policymakers confront the challenge of balancing innovation uptake with fiscal responsibility.

In essence, the study illuminates a vital conversation that must accompany pharmaceutical breakthroughs: how to ensure that life-altering therapies reach those who need them most, regardless of geography or economic status. Without deliberate policy and pricing reforms grounded in value-based principles, the promise of early disease modification in Alzheimer’s may remain an elusive goal for many.

The enduring message from Trinity College Dublin’s research is clear: scientific innovation must be matched by equitable and affordable access frameworks. Only then can the global fight against Alzheimer’s disease transform from incremental progress into a widespread, meaningful victory against a devastating and escalating public health challenge.

News Publication Date: 13-May-2026